| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1085441054 |
| P356 | DOI | 10.1007/S12032-017-0975-5 |
| P698 | PubMed publication ID | 28526922 |
| P50 | author | Giandomenico Roviello | Q41428812 |
| Navid Sobhani | Q47912470 | ||
| P2093 | author name string | D Generali | |
| G Mustacchi | |||
| M Bortul | |||
| F Zanconati | |||
| S P Corona | |||
| A Ianza | |||
| P2860 | cites work | PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 |
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| PD-L1 expression in human cancers and its association with clinical outcomes | Q26738361 | ||
| PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? | Q26741101 | ||
| Profile of palbociclib in the treatment of metastatic breast cancer | Q26747737 | ||
| Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting | Q26747792 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients | Q27824813 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Activating ESR1 mutations in hormone-resistant metastatic breast cancer | Q27852630 | ||
| ESR1 ligand-binding domain mutations in hormone-resistant breast cancer | Q27852637 | ||
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors | Q27853037 | ||
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study | Q27853110 | ||
| Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ... | Q27853272 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA | Q28239638 | ||
| Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis | Q28291864 | ||
| Requirement for CDK4 kinase function in breast cancer | Q28585905 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Fibroblast growth factor signalling: from development to cancer | Q29616827 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Accessories to the crime: functions of cells recruited to the tumor microenvironment | Q29620161 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase | Q30439814 | ||
| Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials | Q32034037 | ||
| Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer | Q33389302 | ||
| Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer | Q33423263 | ||
| Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease | Q33769821 | ||
| Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. | Q33925164 | ||
| The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers | Q33937368 | ||
| Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer | Q33968076 | ||
| Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer | Q34048140 | ||
| Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. | Q34172008 | ||
| Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. | Q34334262 | ||
| Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance | Q34355748 | ||
| PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer | Q34454922 | ||
| Breast cancer metastasis to the central nervous system | Q34455205 | ||
| Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry | Q34503715 | ||
| Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
| Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer | Q34775370 | ||
| Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial | Q35060987 | ||
| The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer | Q35191588 | ||
| Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study | Q35238162 | ||
| Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. | Q35625995 | ||
| A clinically relevant gene signature in triple negative and basal-like breast cancer | Q35683578 | ||
| Prognostic and predictive value of PDL1 expression in breast cancer | Q35741710 | ||
| Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients | Q35749359 | ||
| Leukocyte composition of human breast cancer | Q35779386 | ||
| Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. | Q35889643 | ||
| The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). | Q35965836 | ||
| HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer | Q36040463 | ||
| Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques | Q36108008 | ||
| Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat | Q36245380 | ||
| Resistance to Trastuzumab in Breast Cancer. | Q36318226 | ||
| Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma | Q36333832 | ||
| Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients | Q36642923 | ||
| An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer | Q36643153 | ||
| Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors | Q36694995 | ||
| PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers | Q36840275 | ||
| Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 | ||
| Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer | Q36896150 | ||
| CD4⁺ follicular helper T cell infiltration predicts breast cancer survival | Q36966923 | ||
| Immunological aspects of cancer chemotherapy | Q37039588 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 | ||
| Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry | Q37205563 | ||
| Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models | Q37208563 | ||
| T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. | Q37208738 | ||
| Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis | Q37234841 | ||
| Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer | Q37254804 | ||
| The effect of metformin on apoptosis in a breast cancer presurgical trial. | Q37352586 | ||
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition | Q37445131 | ||
| Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells | Q37456176 | ||
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer | Q37721802 | ||
| PD-L1 expression in triple-negative breast cancer | Q37724790 | ||
| Fibroblast growth factors and their receptors in cancer | Q37895306 | ||
| Beyond trastuzumab: new treatment options for HER2-positive breast cancer | Q37947902 | ||
| The secret ally: immunostimulation by anticancer drugs | Q37981038 | ||
| Hsp90 inhibitors in breast cancer: a systematic review. | Q38122797 | ||
| First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer | Q38247493 | ||
| Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer | Q38259731 | ||
| A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor | Q38279200 | ||
| Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. | Q38379925 | ||
| Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial | Q38388783 | ||
| Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. | Q38393045 | ||
| A gene expression signature identifies two prognostic subgroups of basal breast cancer | Q38506362 | ||
| FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. | Q38793230 | ||
| Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells | Q38868107 | ||
| D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer | Q39064408 | ||
| New protein kinase inhibitors in breast cancer: afatinib and neratinib | Q39200319 | ||
| Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer | Q39520887 | ||
| A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen | Q39584738 | ||
| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 | ||
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind | Q39944735 | ||
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 | ||
| Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. | Q40319552 | ||
| Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. | Q40462527 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes | Q41035618 | ||
| Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer | Q42435519 | ||
| Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome | Q42468745 | ||
| Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. | Q42921828 | ||
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Q43951696 | ||
| HER2 aberrations in cancer: implications for therapy | Q44936056 | ||
| Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group | Q45000497 | ||
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | Q45044547 | ||
| Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 | Q46389190 | ||
| Multifactorial approach to predicting resistance to anthracyclines | Q46579411 | ||
| A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer | Q47762909 | ||
| Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. | Q51357213 | ||
| Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. | Q53084014 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| New Strategies in Breast Cancer: Immunotherapy. | Q54215651 | ||
| Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. | Q54317292 | ||
| Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. | Q54625550 | ||
| Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. | Q55041652 | ||
| Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. | Q55066776 | ||
| Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes | Q57660183 | ||
| An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer | Q73221160 | ||
| Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab | Q80990343 | ||
| The humoral immune system has a key prognostic impact in node-negative breast cancer | Q81561686 | ||
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Q87702640 | ||
| P2507 | corrigendum / erratum | Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives. | Q48039115 |
| P433 | issue | 7 | |
| P921 | main subject | systemic therapy | Q1929812 |
| metastatic breast cancer | Q12859063 | ||
| P304 | page(s) | 119 | |
| P577 | publication date | 2017-05-19 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Advances in systemic therapy for metastatic breast cancer: future perspectives | |
| P478 | volume | 34 |
| Q47912434 | Advances in systemic therapy for malignant mesothelioma: future perspectives |
| Q42683276 | Breast Cancer Vaccines: New Insights |
| Q61446826 | Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches |
| Q90699329 | Impact of breast surgery on survival of patients with stage IV breast cancer: a SEER population-based propensity score matching analysis |
| Q58605259 | Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial) |
| Q61446831 | PUF60 accelerates the progression of breast cancer through downregulation of PTEN expression |
| Q58564534 | Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis |
| Q57183295 | Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens |
| Q48039115 | Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives. | main subject | P921 |
Search more.